首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Frontiers in clinical diabetes and healthcare

缩写:

ISSN:N/A

e-ISSN:2673-6616

IF/分区:3.5/Q2

文章目录 更多期刊信息

共收录本刊相关文章索引393
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Clara S Li,Rose Porta,Shefali Chaudhary Clara S Li
Objectives: Previous studies identified depression and sleep disturbance as risk factors for diabetes. Sleep disturbance and depression are known to be inter-related. Further, women relative to men are more prone to depre...
Antonina Gerganova,Yavor Assyov,Zdravko Kamenov Antonina Gerganova
The novel severe acute respiratory distress syndrome-coronavirus 2 (SARS-CoV-2) has caused one of the most substantial pandemics that has affected humanity in the last century. At the time of the preparation of this review, it has caused th...
Jillian B Halper,Lisa G Yazel,Hala El Mikati et al. Jillian B Halper et al.
Patient engagement in the process of developing a diabetes treatment plan is associated with person-centered care and improved treatment outcomes. The objective of the present study was to evaluate the self-reported patient and parent-cente...
Caroline Cummings,Kagnica Seng,Ryan Tweet et al. Caroline Cummings et al.
Background: The effect of the COVID-19 pandemic on diabetes self-management behaviors is unclear. Objectives: This paper is a scoping r...
Ioanna Farakla,Theano Lagousi,Michael Miligkos et al. Ioanna Farakla et al.
Several recent studies have documented an increased incidence of newly diagnosed type 1 Diabetes (T1D) cases in children and adolescents during the COVID-19 pandemic and a more severe presentation at diabetes onset. In this descriptive stud...
Asger Wretlind,Emilie Hein Zobel,Andressa de Zawadzki et al. Asger Wretlind et al.
Background: Liraglutide is a glucose-lowering medication used to treat type 2 diabetes and obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the incretin system, such as reducing the risk of...
Alfonso Bellia,Marco Meloni,Aikaterini Andreadi et al. Alfonso Bellia et al.
Individuals with diabetes mellitus are at increasing risk for major lower-extremity amputations (LEAs). Poor quality of life and remarkable disabilities are associated with LEAs, determining a high economic burden for the healthcare systems...
Elena Toschi,Jennifer Leblanc,Samar Hafida et al. Elena Toschi et al.
Aims: A multidisciplinary team of clinicians and researchers, patients and family members, and representative from national advocacy groups and research organization met to review the literature, highlight gaps, and ident...